Cecile Idink

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.

A. Kater, C. Mellink, M. Levin, 2018, Blood advances.

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

K. Nasserinejad, A. Kater, D. Issa, 2022, The Lancet. Haematology.

COVID-19 vaccination in patients with immune thrombocytopenia

E. van Werkhoven, F. Leebeek, M. Kruip, 2021, Blood Advances.